sargramostim GZ402664

DRUG2 trials

Sponsors

Sanofi

Conditions

Acute Myeloid Leukemia NOSDementia Alzheimer's Type

Phase 2

Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia

WithdrawnNCT02520102

SanofiAcute Myeloid Leukemia NOS

Start: 2017-02-28End: 2017-02-28Updated: 2017-04-20

Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

WithdrawnNCT02667496

SanofiDementia Alzheimer's Type

Start: 2016-11-30End: 2017-03-31Updated: 2017-04-07